What the research says about TB-500 and thymosin β4

What TB-500 is

TB-500 is described by vendors as a synthetic peptide corresponding to an active region of thymosin β4 (Tβ4), a naturally occurring protein involved in cell migration and tissue repair. It is important to keep the labels straight: the published research is on thymosin β4, and findings for the full protein do not automatically transfer to a fragment sold under a different name ^[1][2].

TB-500 / thymosin β4 is not an approved medicine in the US, EU, or UK, and is offered by third parties for laboratory and research use only. A related thymosin β4 eye-drop candidate has been investigated separately, but that is a distinct, regulated formulation.

What the preclinical research has measured

A 2023 review discussed thymosin β4 in the context of regenerative and anti-aging research, summarizing experimental work rather than controlled human outcomes ^[1]. It frames Tβ4 as a candidate molecule of interest, not a proven therapy.

A review of cardioprotection by thymosin β4 summarized that, in preclinical models of cardiac ischemic injury, injected or transgenic Tβ4 reduced infarct volume and preserved cardiac function, with reported antifibrotic and pro-angiogenic (blood-vessel-growing) activity in animal models and in-vitro assays ^[2]. These are measurements in animals and cells, not in people.

A 2025 study identified the gene encoding thymosin β4 as a possible intervention target in Alzheimer-disease biology using human-derived brain organoids — an in-vitro model built from stem cells, not a clinical trial ^[3]. It is a mechanistic finding in a dish, not evidence of a human treatment effect.

What the research reports on safety and adverse events

There is essentially nothing to report on human safety, and that absence is the finding. The cited literature measured effects in animal models, cell systems, and stem-cell-derived organoids ^[1][2][3]; none of these designs measures adverse events in people. Because there are no controlled human trials of TB-500 or thymosin β4 in this literature, its human adverse-event profile has not been characterized.

There is an added wrinkle specific to TB-500. Much of the research is on the full thymosin β4 protein, while products are sold as a fragment under the TB-500 name, so even the preclinical work does not necessarily describe what is in a given vial ^[1][2]. Reported preclinical activity in models of cardiac injury and regeneration is not evidence of safety in humans ^[2].

Nothing here is a safety claim or medical advice. TB-500 is not an approved medicine and is sold by third parties for laboratory and research use only; anyone weighing it should consult a qualified professional and read the underlying studies directly.

How strong is the evidence

Because the cited literature is essentially all preclinical — animal models, in-vitro assays, and stem-cell-derived organoids, with no controlled human trials — this review is characterized as preclinical only ^[1][2][3]. Findings in animals and cells do not establish that a compound works, is safe, or behaves the same way in people.

There is an additional gap specific to TB-500: much of the research is on the full thymosin β4 protein, while products are sold as a fragment. Nothing here is an endorsement, an efficacy or safety claim, or dosing guidance. Read the underlying studies and consult a qualified professional — this page is a map to the evidence, not a recommendation.